Literature DB >> 10827143

Hepatitis C, interferon alfa, and depression.

D Zdilar1, K Franco-Bronson, N Buchler, J A Locala, Z M Younossi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10827143     DOI: 10.1053/jhep.2000.7880

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  40 in total

1.  Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Authors:  Joseph Rasimas; Antonios Katsounas; Haniya Raza; Alison A Murphy; Jun Yang; Richard A Lempicki; Anu Osinusi; Henry Masur; Michael Polis; Shyam Kottilil; Donald Rosenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

2.  A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.

Authors:  Amira Pierucci-Lagha; Jonathan Covault; Herbert L Bonkovsky; Richard Feinn; Christine Abreu; Richard K Sterling; Robert J Fontana; Henry R Kranzler
Journal:  Psychosomatics       Date:  2010 Mar-Apr       Impact factor: 2.386

3.  Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Authors:  Ondria C Gleason; William R Yates; Michelle A Philipsen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

4.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

5.  Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients.

Authors:  Antonios Katsounas; Joseph J Rasimas; Joerg F Schlaak; Richard A Lempicki; Donald L Rosenstein; Shyam Kottilil
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

6.  Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.

Authors:  T Piche; G Vanbiervliet; F Cherikh; Z Antoun; P M Huet; E Gelsi; J-F Demarquay; F-X Caroli-Bosc; S Benzaken; M-C Rigault; C Renou; P Rampal; A Tran
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

7.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

8.  Fatigue is associated with high circulating leptin levels in chronic hepatitis C.

Authors:  T Piche; E Gelsi; S M Schneider; X Hébuterne; J Giudicelli; B Ferrua; C Laffont; S Benzaken; P Hastier; M L Montoya; F Longo; P Rampal; A Tran
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 9.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Dysregulated relationship of inflammation and oxidative stress in major depression.

Authors:  B J Rawdin; S H Mellon; F S Dhabhar; E S Epel; E Puterman; Y Su; H M Burke; V I Reus; R Rosser; S P Hamilton; J C Nelson; O M Wolkowitz
Journal:  Brain Behav Immun       Date:  2012-11-29       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.